LaserVision

Treatment at a glance

Treatment Time

5 Minutes

Anaesthetic

None

Downtime

None

Longevity

Long Term

Key Benefit

Slows down the rate of visual loss and preserves vision in patients with AMD

What is Valeda Light Delivery System (LDS)?

Developed by LumiThera, the Valeda™ LDS utilises photobiomodulation therapy to target the underlying cellular processes involved in macular degeneration.

Photobiomodulation therapy harnesses the power of low-level light therapy to stimulate cellular function and promote tissue repair by improving metabolism within the mitochondria – the organelles that are responsible for energy production. In the case of macular degeneration, the Valeda™ device delivers precise wavelengths of light to the affected retinal cells, enhancing their metabolic activity and promoting healing. This non-invasive approach offers a promising alternative to traditional treatments like injections or surgery, which can be invasive and carry associated risks.

One of the key advantages of the Valeda™ device is its ability to deliver targeted therapy directly to the site of the degeneration, minimising collateral damage to surrounding tissues. So far, research has shown that PBM therapy attenuates degeneration in sick retina and optic nerve cells, accelerates wound healing, and improves recovery from ischemic injury.

vleda

The use of PBM is a dynamic and growing field of research. The science has been shown to work in vitro, in vivo and in the clinical situation. Clinical trials have shown promising results, with patients experiencing improvements in visual acuity and quality of life.

As of 2024, an estimated 18,000 patients have been treated worldwide with no reported adverse effects. The Valeda™ treatment is extensively used throughout Europe and the rest of the world. The relatively slow uptake of the treatment in the UK is due to the complexity of getting a new treatment code from the NHS. The current president of the Royal College of Ophthalmologists, Professor Ben Burton led the Lightsite II trials, and further, LumiThera and the FDA are now “fast-tracking ” the approval process in the U.S.

As further research and development continue, the Valeda™ device holds the potential to revolutionise the management of macular degeneration, offering hope to millions of individuals worldwide affected by this debilitating condition.

The use of PBM is a dynamic and growing field of research. The science has been shown to work in vitro, in vivo and in the clinical situation. Clinical trials have shown promising results, with patients experiencing improvements in visual acuity and quality of life.

As of 2024, an estimated 18,000 patients have been treated worldwide with no reported adverse effects. The Valeda™ treatment is extensively used throughout Europe and the rest of the world. The relatively slow uptake of the treatment in the UK is due to the complexity of getting a new treatment code from the NHS. The current president of the Royal College of Ophthalmologists, Professor Ben Burton led the Lightsite II trials, and further, LumiThera and the FDA are now “fast-tracking ” the approval process in the U.S.

As further research and development continue, the Valeda™ device holds the potential to revolutionise the management of macular degeneration, offering hope to millions of individuals worldwide affected by this debilitating condition.

Read more
Treatment Benefits Benefits

What are the benefits of Valeda Light Delivery System (LDS)?

  • Non-invasive treatment: Valeda device offers a non-invasive approach to treating macular degeneration, reducing the need for invasive procedures.
  • Enhanced vision: Patients may experience improved vision and visual acuity through targeted light therapy provided by the Valeda device.
  • Convenience: Treatment sessions with the Valeda device are convenient and can be done in clinic, minimising disruption to daily routines.
  • Personalised therapy: The Valeda device allows for personalised treatment plans tailored to each patient's specific needs, optimising outcomes.
  • Minimal side effects: Compared to some traditional treatments, the Valeda device typically carries fewer side effects, enhancing patient comfort and compliance.
  • Long-term management: Utilising the Valeda device for macular degeneration can contribute to long-term management and potentially slow disease progression, offering hope for preserving vision.

How is it performed?

  • 1.Treatment Administration: The patient's eye is positioned in front of the Valeda device, emits multiwavelength LEDs, each treatment lasts less than 5 minutes per eye.
LaserVision-FAQ-Main

Frequently Asked Questions

The Valeda device utilises specific wavelengths of light to stimulate the mitochondrial output to improve retinal cellular function. While it may not be a miracle cure, it has shown promise in slowing down the rate of visual loss in dry macular degeneration.

Yes, the Valeda device is considered safe for use under the guidance of a qualified healthcare professional. It has undergone rigorous testing and clinical trials to ensure its safety and efficacy in treating macular degeneration.

The Valeda device is suitable for individuals diagnosed with macular degeneration, for the dry form of the condition. It can be particularly beneficial for those in the early to intermediate stages of the disease.

The studies demonstrate that a course of 9 sessions is performed over a period of three weeks. Each treatment involves a five-minute session with the Valeda LDS. Patients usually undergo three blocks of treatment each year. Each treatment block aims to slow down the progression of retinal deterioration.

Patients with intermediate dry AMD and those at a high risk of developing geographic atrophy should consider photobiomodulation. While it’s exciting and promising, it’s important to note that its effectiveness may vary from patient to patient and the research is continuing.

​

Patients with reasonably good vision may respond well to photobiomodulation, some even experiencing improved visual acuity. However, those with severe visual loss are not likely to notice significant improvements and visual loss will still progress even with treatment but the hope is that it progresses more slowly than it would without treatment.

The Valeda device is intended to complement existing treatments for macular degeneration rather than replace them. It can be used in conjunction with other therapies such as anti-VEGF injections or nutritional supplements to provide comprehensive care for individuals with macular degeneration. Always consult with a healthcare professional to determine the most suitable treatment plan for your specific needs.

Treatment Options

Choosing the right vision correction clinic for your surgery is paramount. This is a life changing procedure after all, and you need to have complete trust in your surgeon and care team of professionals.

Previous Slide Next Slide

Related Concerns

Choosing the right vision correction clinic for your surgery is paramount. This is a life changing procedure after all, and you need to have complete trust in your surgeon and care team of professionals.

Previous Slide Next Slide
Events

Patient Experience

Laser Vision

New Treatment!

We are delighted to announce that Laser Vision has introduced VALEDA for Dry AMD.

As one of the only clinics in the UK to have this device, we are privileged to once again be leading the way as VALEDA LDS (Light Delivery System) offers hope to those battling Dry AMD, providing innovative therapy for vision preservation. Developed by leading experts, this cutting-edge device promises enhanced outcomes and improved quality of life.

Discover the future of AMD treatment with VALEDA, now available at Laser Vision.

FIND OUT MORE